These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2958861)

  • 21. Complete androgen blockade: the EORTC experience comparing orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose stilboestrol in the treatment of metastatic carcinoma of the prostate.
    Robinson MR
    Prog Clin Biol Res; 1987; 243A():383-90. PubMed ID: 2958863
    [No Abstract]   [Full Text] [Related]  

  • 22. [Treatment of prostatic cancer].
    J Urol (Paris); 1984; 90(10):619-48. PubMed ID: 6242517
    [No Abstract]   [Full Text] [Related]  

  • 23. Re: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762.
    deVoogt HJ; Pavone-Macaluso M; Sylvester R; Schröder FH
    J Urol; 1988 Dec; 140(6):1557. PubMed ID: 2973530
    [No Abstract]   [Full Text] [Related]  

  • 24. [Fatal subfulminant hepatitis caused by cyproterone acetate].
    Antoni M; Bourlière M; Toullec J; Maillot A; Botta-Fridlund D; Gauthier A
    Gastroenterol Clin Biol; 1991; 15(10):772-3. PubMed ID: 1840042
    [No Abstract]   [Full Text] [Related]  

  • 25. [Cyproterone acetate in the treatment of post-orchiectomy flushing].
    Jansen JE; Hendriksen ON
    Ugeskr Laeger; 1989 Feb; 151(9):560-1. PubMed ID: 2522257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer.
    Moffat LE
    Eur Urol; 1990; 18 Suppl 3():26-7. PubMed ID: 2151272
    [No Abstract]   [Full Text] [Related]  

  • 27. Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
    de Voogt HJ; Pavone-Macaluso M; Smith PH; de Pauw M; Suciu S
    Prog Clin Biol Res; 1988; 260():111-7. PubMed ID: 2966403
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of symptomatic metastatic prostatic cancer with cyproterone acetate versus orchiectomy: a prospective randomized trial.
    Ostri P; Bonnesen T; Nilsson T; Frimodt-Møller C
    Urol Int; 1991; 46(2):167-71. PubMed ID: 1711250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of cancer of the prostate. New hormonal approaches].
    Schaison G
    Pathol Biol (Paris); 1989 Feb; 37(2):118-9. PubMed ID: 2523530
    [No Abstract]   [Full Text] [Related]  

  • 30. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM
    Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breathlessness in patients with prostatic carcinoma treated with cyproterone acetate.
    Green NA; Harrison BD
    BMJ; 1989 Jun; 298(6686):1524. PubMed ID: 2527069
    [No Abstract]   [Full Text] [Related]  

  • 32. [Evaluation of efficacy of cyproterone acetate monotherapy in prostatic cancer].
    Gurina LI; Iudin SV; Rusakov IG; Bystrov AA
    Urologiia; 2003; (4):25-30. PubMed ID: 12942722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of cyproterone/acetate (SH-714) on plasma prolactin in patients with prostatic cancer.
    Holub G; Lunglmayr G; Spona J
    Urol Res; 1981; 9(5):245-7. PubMed ID: 6458145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe hepatocellular dysfunction following cyproterone acetate therapy.
    Parys BT; Hamid S; Thomson RG
    Br J Urol; 1991 Mar; 67(3):312-3. PubMed ID: 1827039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Serum prolactin levels during therapy of prostatic cancer with oestradiol-17 beta-undecylate and cyproterone acetate (author's transl)].
    Spona J; Lunglmayr G
    Wien Klin Wochenschr; 1980 Jul; 92(14):494-7. PubMed ID: 6933738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843.
    de Voogt HJ; Klijn JG; Studer U; Schröder F; Sylvester R; De Pauw M
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):965-9. PubMed ID: 2149509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatocellular carcinoma and treatment with cyproterone acetate.
    Ohri SK; Gaer JA; Keane PF
    Br J Urol; 1991 Feb; 67(2):213. PubMed ID: 1848454
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R
    J Urol; 1986 Sep; 136(3):624-31. PubMed ID: 2942707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decrease of serum testosterone by cyproterone acetate accompanied by an unexpected increase of calcitonin secretion capacity.
    Mulder H; Eland D; Hackeng WH; Schopman W
    J Urol; 1987 Aug; 138(2):324-5. PubMed ID: 2955132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hepatitis after treatment with cyproterone acetate. Apropos of a case].
    Dore B; Orget J; Irani J; Aubert J
    J Urol (Paris); 1990; 96(3):169-71. PubMed ID: 2145371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.